IVIG
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinocerebellar Ataxia
Conditions
Spinocerebellar Ataxia
Trial Timeline
Aug 1, 2011 → Jul 1, 2013
NCT ID
NCT01350440About IVIG
IVIG is a phase 2 stage product being developed by Baxter for Spinocerebellar Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT01350440. Target conditions include Spinocerebellar Ataxia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01545518 | Phase 2 | Terminated |
| NCT01350440 | Phase 2 | Completed |
Competing Products
15 competing products in Spinocerebellar Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2 | 51 |
| BIIB132 + BIIB132-Matching Placebo | Biogen | Phase 1 | 30 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 30 |
| ARO-ATXN2 Injection + Placebo | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| Troriluzole + Placebo + Troriluzole | Biohaven | Phase 2/3 | 60 |
| BHV-4157 | Biohaven | Pre-clinical | 18 |
| troriluzole + Placebo | Biohaven | Phase 3 | 72 |